Haemonetics stock came into this quarter on a tear, with shares up almost 60% over the past three months and another 3.3% added today. That kind of move sets a high bar. The headline from the print is straightforward: revenue reached US$339.4m and adjusted earnings per share landed at US$1.14, while management pushed full year revenue guidance higher.

For a company long viewed as a steady blood and plasma technology compounder, the real story this quarter is not a growth scare. Instead, it is the strength of free cash flow and rising confidence in the durability of that growth.

Is Haemonetics a genuine bargain at a reported 50% discount to DCF fair value, or are the thinner 7.1% net margins and one off loss sending an early warning? Compare the current share price, earnings path and peer P/E in the valuation analysis for Haemonetics

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: US$339.38m vs. US$321.39m (up about 5.6%)
• Net Income, Q1 2027 vs. Q1 2026: US$33.01m vs. US$34.03m (down about 3.0%)
• Basic EPS, Q1 2027 vs. Q1 2026: US$0.73 vs. US$0.71 (up about 2.9%)
• Net Profit Margin, Trailing 12 Months vs. Prior Year: 7.1% vs. 12.1% (margin contracted)

Prefer clean charts over another wall of earnings tables and margin figures? See how Haemonetics stacks up at a glance, including a visual breakdown of its valuation and cash generation profile, in the company report for Haemonetics.

Haemonetics bull case leans on cash and execution

Bulls argue Haemonetics is turning plasma and MedSurg momentum into durable, higher quality growth supported by index inclusion and buybacks. The Q1 print gives that view some concrete support. Revenue grew 6% on both reported and organic bases, and adjusted EPS was US$1.14, in line with a story of steady compounding rather than a one off spike. Plasma disposables grew strongly, helped by Persona PLUS and share gains in North America and EMEA, which fits the thesis that NexSys and software contracts are building a recurring base. MedSurg also contributed, with hemostasis disposables and vascular closure both growing and VASCADE MVP XL backed by new Emory data and an expanded FDA label. The most powerful proof point is cash. Operating cash flow roughly tripled versus last year and trailing 12 month free cash flow conversion reached about 106%, which supports claims that earnings quality is improving, not just EPS optics from prior buybacks.

Bear case focuses on margins, mix and concentration

Bears worry that Haemonetics relies too much on a concentrated U.S. hospital and plasma footprint, with underperforming segments and structurally pressured margins. The quarter does not clear that risk. Net income of US$33.01m was slightly below the prior year despite higher revenue, and the trailing 12 month net margin sits at 7.1% compared with 12.1% a year ago. That contraction backs concerns about pricing pressure, competition and cost inflation, even as the company points to underlying adjusted margin expansion once a prior software benefit is removed. Interventional Technologies grew only low single digits, with softness in peripheral and coronary products still visible, so the recovery in vascular closure is not yet broad based. Management also kept plasma volume assumptions at 0 to 2% for the year, which acknowledges that part of the current Apheresis strength reflects share and yield gains in a cyclical and flat volume market.

After a margin reset like this, are Haemonetics’ pressures contained or part of a deeper pattern? Review our independent risk analysis for Haemonetics which shows 3 important warning signs

Stay Ahead With Simply Wall St

If the mix of strong free cash flow and thinner margins at Haemonetics has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and set your own preferred entry window. Once you are invested, use the Portfolio Command Center to keep the focus on key fundamental developments and portfolio level risks instead of short term headlines. For a broader view on what other investors are seeing in Haemonetics and similar stocks, tap into the Community and compare your thesis with real world perspectives. This way you spot potential catalysts and emerging risks earlier and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Haemonetics?

Fresh ideas can move quickly, and the stocks drawing quiet attention today can be the ones breaking out tomorrow. Scan these curated shortlists before the crowd and act now.

• Spot established payout machines with yields that may support income while prices are still settling by checking the 8 dividend fortresses.
• Track companies where strong balance sheets and fundamentals meet potential price gaps and see which ones still look overlooked through the 49 high quality undervalued stocks.
• Zero in on businesses with resilient profiles that aim to limit downside swings using the curated 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.